Growth Metrics

Elicio Therapeutics (ELTX) Debt Ratio (2020 - 2026)

Elicio Therapeutics posted quarterly Debt Ratio of 0.42 for Q1 2026, up 14.81% on a QoQ basis from 0.36 in Q4 2025.

Elicio Therapeutics (ELTX) has 4 years of Debt Ratio data on file, last reported at 0.42 in Q1 2026.

  • For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 0.42; the trailing twelve-month figure through Mar 2026 stood at 0.42 (changed N/A YoY), and the FY2025 full-year result was 0.36, down 48.84% from the prior year.
  • Debt Ratio for Q1 2026 stood at 0.42, up from 0.36 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.71 in Q4 2024 and bottomed at 0.32 in Q2 2025.
  • The 3-year median for Debt Ratio is 0.36 (2025), against an average of 0.43.
  • Peak annual rise in Debt Ratio reached 48.84% in 2025, while the deepest fall reached 48.84% in 2025.
  • A 3-year view of Debt Ratio shows it stood at 0.71 in 2024, then plunged by 48.84% to 0.36 in 2025, then rose by 14.81% to 0.42 in 2026.
  • The last three Debt Ratio figures came in at 0.42 (Q1 2026), 0.36 (Q4 2025), and 0.34 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.18
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 1.41
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.05
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Elicio Therapeutics 217.63 Mn 202.68 Mn - 0.42

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.42
Dec 31, 2025 0.36
Sep 30, 2025 0.34
Jun 30, 2025 0.32
Dec 31, 2024 0.71
Dec 31, 2020 0.01